VitaDX has developed VisioCyt Bladder, a software that uses artificial intelligence to support improved diagnosis of bladder cancer. The company is based in Rennes and employs about twenty people. It is accelerating commercial deployment in France following its reimbursement listing and is preparing a launch in the United States. To support these plans it recently raised new funding and previously completed a larger raise in spring 2024. Management changes have been announced alongside the financing, with Fabrice Beauchêne recruited to the chief executive role and Allan Rodriguez moving to chairman of the board.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2025